HGFR/c-MET Antibody (SJ19-05)

Western Blot: HGFR/c-MET Antibody (SJ19-05) [NBP2-67412] - Western blot analysis of HGFR/c-MET on different lysates. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody (1/500) was used in 5% BSA at room temperature for 2 hours. Goat Ant

Immunocytochemistry/Immunofluorescence: HGFR/c-MET Antibody (SJ19-05) [NBP2-67412] - Staining Met in Hela cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.

Immunohistochemistry-Paraffin: HGFR/c-MET Antibody (SJ19-05) [NBP2-67412] - Analysis of paraffin-embedded human tonsil tissue using anti-Met antibody. Counter stained with hematoxylin.

Flow Cytometry: HGFR/c-MET Antibody (SJ19-05) [NBP2-67412] - Flow cytometric analysis of HGFR/c-MET was done on Hela cells. The cells were fixed, permeabilized and stained with the primary antibody (1/50) (red). After incubation of the primary antibody at room temperature for an hour, the cells were stained with a Alexa Fluor 488-conjugated Goat anti-Rabbit IgG Secondary antibody at 1/1000 dilution for 30 minutes. Unlabeled sample was used as a control (cells without incubation with primary antibody; black).

Western Blot: HGFR/c-MET Antibody (SJ19-05) [NBP2-67412] - Analysis of Met on different lysates using anti-Met antibody at 1/1,000 dilution. Positive control: Lane 1: Hela Lane 2: HepG2

Immunohistochemistry-Paraffin: HGFR/c-MET Antibody (SJ19-05) [NBP2-67412] - Analysis of paraffin-embedded human breast carcinoma tissue using anti-Met antibody. Counter stained with hematoxylin.

Immunohistochemistry-Paraffin: HGFR/c-MET Antibody (SJ19-05) [NBP2-67412] - Analysis of paraffin-embedded human liver cancer tissue using anti-Met antibody. Counter stained with hematoxylin.

Immunohistochemistry-Paraffin: HGFR/c-MET Antibody (SJ19-05) [NBP2-67412] - Analysis of paraffin-embedded human lung cancer tissue using anti-Met antibody. Counter stained with hematoxylin.

Flow Cytometry: HGFR/c-MET Antibody (SJ19-05) [NBP2-67412] - Analysis of Hela cells with Met antibody at 1/50 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black). Alexa Fluor 488-conjugated goat anti rabbit IgG was used as the secondary antibody.

Product Discontinued

HGFR/c-MET Antibody (SJ19-05) Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Synthetic peptide within C-terminal human HGFR/c-MET. (SwissProt: P08581 Human)
• Localization: Membrane, Secreted.
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Gene: MET
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 1:50-1:100
  • Immunocytochemistry/ Immunofluorescence 1:50-1:200
  • Immunohistochemistry
  • Immunohistochemistry-Paraffin 1:50-1:200
  • Western Blot 1:1000-1:5000

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: TBS (pH7.4), 0.05% BSA, 40% Glycerol
• Preservative: 0.05% Sodium Azide
• Concentration: 1 mg/ml
• Purity: Protein A purified

Alternate Names for HGFR/c-MET Antibody (SJ19-05)

• AUTS9
• cMET
• c-MET
• EC 2.7.10
• EC 2.7.10.1
• hepatocyte growth factor receptor
• HGF R
• HGF receptor
• HGF/SF receptor
• HGFR
• Met (c-Met)
• met proto-oncogene (hepatocyte growth factor receptor)
• met proto-oncogene tyrosine kinase
• MET
• oncogene MET
• Proto-oncogene c-Met
• RCCP2
• Scatter factor receptor
• SF receptor
• Tyrosine-protein kinase Met

Background

Met is a receptor protein-tyrosine kinase (RPTK) for hepatocyte growth factor (HGF), which is a multifunctional cytokine controlling cell growth, morphogenesis, and motility. Met overexpression has been identified in a variety of human cancers (1). Met kinase domain possesses unique features that distinguish met from other members of the src family of protein tyrosine kinases. These results also demonstrate that the product of the activated met gene is a fusion protein and that the amino terminal end of this fusion protein exhibits homology to laminin B1 (2). Data suggest that RanBP9, functioning as an adaptor protein for the Met tyrosine kinase domain, can augment the HGF-Met signaling pathway and that RanBP9 overexpression may cause constitutive activation of the Ras signaling pathway (1). Hereditary papillary renal carcinoma (HPRC) is a recently recognized form of inherited kidney cancer Results suggest that missense mutations located in the MET proto-oncogene lead to constitutive activation of the Met protein and papillary renal carcinomas (3)

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: MET